Deutsche Bank analyst Christopher Barnes maintains Dole (NYSE:DOLE) with a Buy and lowers the price target from $17 to $15.
Baird Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $35
Baird analyst Brian Skorney maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $52 to $35.